Etripamil - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for etripamil and what is the scope of freedom to operate?
Etripamil
is the generic ingredient in one branded drug marketed by Milestone Pharms Usa and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.One supplier is listed for this compound.
Summary for etripamil
| International Patents: | 66 |
| US Patents: | 6 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 10 |
| Patent Applications: | 15 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for etripamil |
| What excipients (inactive ingredients) are in etripamil? | etripamil excipients list |
| DailyMed Link: | etripamil at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for etripamil
Generic Entry Date for etripamil*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
SPRAY;NASAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for etripamil
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Milestone Pharmaceuticals Inc. | PHASE3 |
| Milestone Pharmaceuticals Inc. | Phase 1 |
| Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for etripamil
US Patents and Regulatory Information for etripamil
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Milestone Pharms Usa | CARDAMYST | etripamil | SPRAY;NASAL | 218571-001 | Dec 12, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Milestone Pharms Usa | CARDAMYST | etripamil | SPRAY;NASAL | 218571-001 | Dec 12, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Milestone Pharms Usa | CARDAMYST | etripamil | SPRAY;NASAL | 218571-001 | Dec 12, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Milestone Pharms Usa | CARDAMYST | etripamil | SPRAY;NASAL | 218571-001 | Dec 12, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Milestone Pharms Usa | CARDAMYST | etripamil | SPRAY;NASAL | 218571-001 | Dec 12, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for etripamil
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2008266798 | Short acting phenylalkylamine calcium channel blockers and uses thereof | ⤷ Start Trial |
| Brazil | PI0812919 | BLOQUEADORES DE CANAL DE CÁLCIO DE FENILALQUILAMINA DE AÇÃO CURTA E USO DOS MESMOS | ⤷ Start Trial |
| Canada | 2693627 | AGENTS BLOQUANT LES CANAUX CALCIQUES A BASE DE PHENYLALKYLAMINE A BREVE DUREE D'ACTION ET LEURS UTILISATIONS (SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF) | ⤷ Start Trial |
| China | 101754678 | Short acting phenylalkylamine calcium channel blockers and uses thereof | ⤷ Start Trial |
| Cyprus | 1115619 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
